| James Frederick Harris, MD | |
|
221 5th Ave S, Glasgow, MT 59230-2600 | |
| (406) 228-3536 | |
| (406) 228-3537 |
| Full Name | James Frederick Harris |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 26 Years |
| Location | 221 5th Ave S, Glasgow, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083750830 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 01052579A (Indiana) | Secondary |
| 207X00000X | Orthopaedic Surgery | 89989 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Frances Mahon Deaconess Hospital | Glasgow, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Frances Mahon Deaconess Hospital | 3173430949 | 35 |
News Archive
Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient's own immune cells to fight cancer.
A researcher at the University of Cincinnati is looking at ways to make products such as anti-aging and skin lightening creams, lotions, and gels more effective.
Insurance status is a better predictor of survival after a serious cardiac event than race, and may help explain racial disparities in health outcomes for cardiovascular disease. A new study by Derek Ng, from the Johns Hopkins Bloomberg School of Public Health in the US, and his team shows that race is not linked to an increased risk of death but being underinsured is a strong predictor of death among those admitted into hospital with a serious cardiac event.
Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.
› Verified 8 days ago
| Entity Name | Frances Mahon Deaconess Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639117013 PECOS PAC ID: 3173430949 Enrollment ID: O20031111000918 |
News Archive
Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient's own immune cells to fight cancer.
A researcher at the University of Cincinnati is looking at ways to make products such as anti-aging and skin lightening creams, lotions, and gels more effective.
Insurance status is a better predictor of survival after a serious cardiac event than race, and may help explain racial disparities in health outcomes for cardiovascular disease. A new study by Derek Ng, from the Johns Hopkins Bloomberg School of Public Health in the US, and his team shows that race is not linked to an increased risk of death but being underinsured is a strong predictor of death among those admitted into hospital with a serious cardiac event.
Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Frederick Harris, MD 221 5th Ave S, Glasgow, MT 59230-2600 Ph: (406) 228-3536 | James Frederick Harris, MD 221 5th Ave S, Glasgow, MT 59230-2600 Ph: (406) 228-3536 |
News Archive
Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient's own immune cells to fight cancer.
A researcher at the University of Cincinnati is looking at ways to make products such as anti-aging and skin lightening creams, lotions, and gels more effective.
Insurance status is a better predictor of survival after a serious cardiac event than race, and may help explain racial disparities in health outcomes for cardiovascular disease. A new study by Derek Ng, from the Johns Hopkins Bloomberg School of Public Health in the US, and his team shows that race is not linked to an increased risk of death but being underinsured is a strong predictor of death among those admitted into hospital with a serious cardiac event.
Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.
› Verified 8 days ago
Dr. Brean Drew Mccarthy, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 221 5th St S, Glasgow, MT 59230 Phone: 406-228-3400 | |
Dr. Curtis R Settergren, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 221 5th Ave S, Glasgow, MT 59230 Phone: 406-228-3536 Fax: 406-228-3537 |